— ‘Coming Soon’ placeholders for all three SKUs of VAZALORE to be positioned prominently on shelves —
SPARTA, N.J., July 26, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), today announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 2,400 Rite Aid stores later in August.
Rite Aid is also reserving shelf space with “Coming Soon” placeholders for all three SKUs — VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count – to alert consumers about the new aspirin therapy that will soon be available.
“Our commercial launch plans are well under way, and we are delighted that Rite Aid is preparing its stores for VAZALORE later this summer. We look forward to adding Rite Aid to the growing number of retail pharmacy leaders that are providing access to this innovative aspirin therapy,” stated Natasha Giordano, Chief Executive Officer of PLx.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63eb4491-f9b7-4c20-9a6b-5cf48bc22c80